Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

Apoptosis

Volumn 9, Issue 6, 2004, Pages 797-805

  Aguirre, D ^a   Boya, P ^a   Bellet, D ^a   Faivre, S ^a   Troalen, F ^a   Benard, J ^a   Saulnier, P ^a   Hopkins Donaldson, S ^b   Zangemeister Wittke, U ^b   Kroemer, G ^a   Raymond, E ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apoptosis; Cell cycle; Gene expression; RAD001; Rapamycin; Surrogate marker

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EVEROLIMUS; PROTEIN BCL 2; RAPAMYCIN; ANTINEOPLASTIC ANTIBIOTIC; ANTISENSE OLIGONUCLEOTIDE; CDK4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; DRUG DERIVATIVE; MESSENGER RNA; ONCOPROTEIN; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G1 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EVALUATION; FOLLOW UP; GENE EXPRESSION PROFILING; GENETIC CODE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; CARCINOMA; CELL DEATH; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; IC 50; METABOLISM; OVARY TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CARCINOMA; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SIROLIMUS; TRANSFECTION;

EID: 16444379884     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:APPT.0000045781.46314.e2     Document Type: Article

References (23)

1. Mills GB, Lu Y, Fang X, et al. The role of genetic abnormalities of PTEN and the phospatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Seminars in Oncol 2001; 28(suppl 16): 125-141.
2. Hu L, Zaloudek C, Mills G, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by aphosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000; 6(3): 880-886.
3. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR). Pro-and anti-apoptotic. Cell Death Differ 2002; 9: 99-100.
4. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increase sensitivity to cisplatin in vitro. Cancer Res 1995; 55(9): 1982-1988.
5. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 2002; 62: 1087-1092.
6. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19(56): 6680-6686.
7. Majewski M, Korecka M, Kossev P, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-barr virus-transformed B lymphocytes in vitro and in vivo: Potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000; 97(8): 4285-4290.
8. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98(18): 10314-10319.
9. +/- mice. Proc Natl Acad Sci USA 2001; 98(18): 10320-10325.
10. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001; 7(6): 1758-1764.
11. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res 2001; 61(8): 3373-3381.
12. Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacology 1998; 54: 815-824.
13. Castedo T, Roumier J, Blanco KF, et al. Sequential involvement of Cdkl, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 2002; 21: 4070-4080.
14. L antagonize the mitochondnal dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997; 57: 62-67.
15. Chan T-F, Carvalho J, Riles L, Zheng XSF. A chemical genomics approach toward understanding the global functions of the target of rapamycin protein (TOR). Proc Natl Acad Sci USA 2000; 97(24): 13227-13232.
16. Hardwick JS, Kuruvilla FG, Tong JK, Shamji AF, Schreiber SL. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc Natl Acad Sci USA 1999; 96(26): 14866-14870 (http://www.pnas.org/cgi/content/full/96/26/14866/ DC1).
17. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000; 6: 2547-2555.
18. Gautschi O, Tschopp S, Olie RA, et al. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst 2001; 93: 463-471.
19. Shinjyo T, Kuribara R, Inukai T, et al. Downregulation of bim, a proapoptotic relative of Bcl-2, is a pivotal step in cytokine-initiated survival signaling in murine hematopoietic progenitors. Mol Cell Biol 2001; 21(3): 854-864.
20. Shinoura N, Yoshida Y, Nishimura M, et al. Expression level of bcl-2 determines anti- or proapoptotic function. Cancer Res 1999; 59: 4119-4128.
21. Torgler R, Jakob S, Ontsouka E, et al. Regulation of activation-induced Fas (CD95/Apo-1) ligand expression in T cells by the Cyclin B1/cdk1 complex. J Biol Chem 2004; Epub ahead of print June 23.
22. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Medicine 2004; 10(6): 594-601.
23. Raymond E, Alexandre J, Faivre S, et al. Safety and Pharmacokinetics of Escalated Doses of Weekly Intravenous Infusion of CCI-779, a Novel mTOR Inhibitor, in Patients With Cancer. J Clin Oncol 2004; 22(12): 2336-2347.